Literature DB >> 15958652

Increased cathepsin D release by Hyp mouse osteoblast cells.

Naoko Matsumoto1, Oak D Jo, Remi N J Shih, Elsa J Brochmann, Samuel S Murray, Victor Hong, Jane Yanagawa, Norimoto Yanagawa.   

Abstract

The X-linked hypophosphatemia (XLH), the most common form of hereditary rickets, is caused by loss-of-function mutations of PHEX (phosphate-regulating gene with homology to endopeptidases on the X chromosome) leading to rachitic bone disease and hypophosphatemia. Available evidence today indicates that the bone defect in XLH is caused not only by hypophosphatemia and altered vitamin D metabolism but also by factor(s) locally released by osteoblast cells (ObCs). The identity of these ObC-derived pathogenic factors remains unclear. In our present study, we report our finding of a prominent protein in the culture media derived from ObC of the hypophosphatemic (Hyp) mice, a murine homolog of human XLH, which was identified as the murine procathepsin D (Cat D). By metabolic labeling studies, we further confirmed that Hyp mouse ObCs released greater amount of Cat D into culture media. This increased Cat D release by Hyp mouse ObCs was unlikely to be due to nonspecific cell damage or heterogeneous cell population and was found to be associated with an increased Cat D expression at the protein level, possibly due to a reduced Cat D degradation. However, we were not able to detect a direct effect of PHEX protein on Cat D cleavage. In support of the involvement of Cat D in mediating the inhibitory effect of Hyp mouse ObC-conditioned media on ObC calcification, we found that exposure to Cat D inhibited ObC (45)Ca incorporation and that inhibition of Cat D abolished the inhibitory effect of Hyp mouse-conditioned media on ObC calcification. In conclusion, results from our present study showed that Hyp mouse ObCs release a greater amount of Cat D, which may contribute to the inhibitory effect of Hyp mouse ObC-conditioned media on ObC mineralization.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15958652     DOI: 10.1152/ajpendo.00562.2004

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  7 in total

1.  ASARM peptides: PHEX-dependent and -independent regulation of serum phosphate.

Authors:  Valentin David; Aline Martin; Anne-Marie Hedge; Marc K Drezner; Peter S N Rowe
Journal:  Am J Physiol Renal Physiol       Date:  2010-12-22

2.  Correction of the mineralization defect in hyp mice treated with protease inhibitors CA074 and pepstatin.

Authors:  Peter S N Rowe; Naoko Matsumoto; Oak D Jo; Remi N J Shih; Jeannine Oconnor; Martine P Roudier; Steve Bain; Shiguang Liu; Jody Harrison; Norimoto Yanagawa
Journal:  Bone       Date:  2006-06-09       Impact factor: 4.398

Review 3.  Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway.

Authors:  Peter S N Rowe
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2012       Impact factor: 1.807

4.  Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP.

Authors:  Aline Martin; Valentin David; Jennifer S Laurence; Patricia M Schwarz; Eileen M Lafer; Anne-Marie Hedge; Peter S N Rowe
Journal:  Endocrinology       Date:  2007-12-27       Impact factor: 4.736

5.  Matrix extracellular phosphoglycoprotein (MEPE) is a new bone renal hormone and vascularization modulator.

Authors:  Valentin David; Aline Martin; Anne-Marie Hedge; Peter S N Rowe
Journal:  Endocrinology       Date:  2009-06-11       Impact factor: 4.736

Review 6.  The chicken or the egg: PHEX, FGF23 and SIBLINGs unscrambled.

Authors:  Peter S N Rowe
Journal:  Cell Biochem Funct       Date:  2012-05-09       Impact factor: 3.685

7.  Systemic transplantation of human adipose-derived stem cells stimulates bone repair by promoting osteoblast and osteoclast function.

Authors:  Kyunghee Lee; Hyunsoo Kim; Jin-Man Kim; Jae-Ryong Kim; Keuk-Jun Kim; Yong-Jin Kim; Se-Il Park; Jae-Ho Jeong; Young-mi Moon; Hyun-Sook Lim; Dong-Won Bae; Joseph Kwon; Chang-Yong Ko; Han-Sung Kim; Hong-In Shin; Daewon Jeong
Journal:  J Cell Mol Med       Date:  2011-10       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.